<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268563</url>
  </required_header>
  <id_info>
    <org_study_id>11367</org_study_id>
    <nct_id>NCT04268563</nct_id>
  </id_info>
  <brief_title>Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients</brief_title>
  <official_title>Comparing the Therapeutic Effect of Sitagliptin/Metformin and Metformin on Biochemical Factors and Expression of GDF-9 and BMP-15 Genes in Patients With Classic PCOS Undergoing Intra-cytoplasmic Sperm Injection (ICSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will evaluate and compare the efficacy of Sitagliptin/Metformin to metformin
      and sitagliptin on gdf9 and bmp15 gene expression on PCOS patients undergoing
      intracytoplasmic sperm injection(ICSI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted in Infertility clinic of Mahdiyeh Educational Hospital, Tehran.
      Patients in the four groups receive the drug 2 months before the start of the ovulation
      cycle, and treatment will continue until the day of the oocyte aspiration. The drug provide
      by midwife to patients and both patient and physician blind to the treatment regimen. The
      participants randomly divide into four groups.The ovulation induction stimulate with GnRh
      antagonist.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>24 hours after last dose</time_frame>
    <description>ELIZA hormone assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth differentiation factor-9(GDF-9) expression</measure>
    <time_frame>24 hours after last dose</time_frame>
    <description>Realtime PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone morphogenetic protein-15(BMP-15) expression</measure>
    <time_frame>24 hours after last dose</time_frame>
    <description>Realtime PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Testosterone</measure>
    <time_frame>24 hours after last dose</time_frame>
    <description>ELIZA hormone assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follicle-stimulating hormone(FSH)</measure>
    <time_frame>24 hours after last dose</time_frame>
    <description>ELIZA hormone assay</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Infertility</condition>
  <condition>ART</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group 1: received Metformin (Glucophage, Merck, West Drayton, UK; 500 mg ,two times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group2: received Sitagliptin (Januvia, Merck,West Drayton, UK. 50 mg, two times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sitagliptin/metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group3: received Sitagliptin/metformin (Janumet, Merck,West Drayton, UK. 50/500 mg), two times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral rehydration solution</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>rehydration solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin tablet</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin tablet</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>JANUVIA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin/metformin</intervention_name>
    <description>Sitagliptin/metformin tablet</description>
    <arm_group_label>sitagliptin/metformin</arm_group_label>
    <other_name>JANUMET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject has clinical or biochemical hyperandrogenic symptoms

          -  subject has oligo/amenorrhea cycles

        Exclusion Criteria:

          -  Hypersensitivity to metformin

          -  Hypersensitivity to sitagliptin presence of infertility factors other than
             anovulation,

          -  male infertility

          -  pelvic organic pathologies

          -  congenital adrenal hyperplasia

          -  thyroid dysfunction

          -  Cushing's syndrome

          -  hyper prolactinemia

          -  androgen secreting neoplasia

          -  diabetes mellitus

          -  consumption of medications affecting carbohydrate metabolism

          -  consumption hormonal analogues other than progesterone 2 months prior to enrolment in
             the study

          -  severe hepatic

          -  pancreatitis

          -  kidney diseases

          -  gallbladder diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Study is based women with polycystic ovary syndrome.</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahrzad Shahrzad Zadehmodarres, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Delbar Daneshjou, PHD student</last_name>
    <phone>989120823342</phone>
    <email>db.daneshjou@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mahdiyeh educational hospital</name>
      <address>
        <city>Tehran</city>
        <zip>1989930002</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delbar Daneshjou, PHD student</last_name>
      <phone>989120823342</phone>
      <email>db.daneshjou@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Delbar Daneshjou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Intracytoplastic sperm injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

